HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Relationship between cancer and oral pemphigoid patients with antibodies to alpha6-integrin.

AbstractBACKGROUND:
Mucous membrane pemphigoid is an autoimmune mucocutaneous blistering disease. A subset, known as anti-epiligrin cicatricial pemphigoid is associated with a high risk for malignancy. Oral pemphigoid (OP) is limited to the oral cavity. The purpose of this study was to determine the association between malignancy and patients with OP with antibodies to alpha6-integrin subunit.
METHODS:
We determined the incidence of cancer in 72 patients with OP and compared it to the expected incidence using age and sex-specific rates of malignancy in the National Cancer Institute's Surveillance, Epidemiology, and End Results (NCI SEER) Registry.
RESULTS:
During a mean observation period of 9.1 years (range: 2.8-40), for 70, three OP patients developed malignancies. The expected number of cancers based on the NCI SEER Registry was 8.83. The relative risk for cancer in OP patients, with autoantibodies to alpha6-integrin, was 0.34 (95% CI, 0.07-0.99, P < 0.05).
CONCLUSION:
It appears that patients with OP, with antibodies to alpha6, may have a possible reduced relative risk for developing cancer.
AuthorsMohsin Malik, Hakan M Gürcan, William Christen, A Razzaque Ahmed
JournalJournal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (J Oral Pathol Med) Vol. 36 Issue 1 Pg. 1-5 (Jan 2007) ISSN: 0904-2512 [Print] Denmark
PMID17181734 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Autoantibodies
  • Integrin alpha6
Topics
  • Adult
  • Age Factors
  • Aged
  • Autoantibodies (analysis)
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Integrin alpha6 (analysis)
  • Male
  • Middle Aged
  • Mouth Diseases (complications, immunology)
  • Neoplasms (etiology)
  • Pemphigoid, Bullous (complications, immunology)
  • Retrospective Studies
  • Risk Factors
  • SEER Program
  • Sex Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: